On May 19, 2017, Amhwa Biology received the DMF filing Registration Number confirmation letter from the US FDA, informing Amhwa Biology that it had obtained the DMF filing registration number 031799.

This means that Amhwa Biology's flagship product hyaluronic acid is ready to enter the US market, and then expand to the EU market and other international markets, and also shows that the production quality of our hyaluronic acid products and the overall management level of the enterprise have met the highest international quality certification level, which is the result of careful management and accumulation of Amhwa Biology for many years. It has laid a solid foundation for establishing a good international market image of enterprises.

According to the unified deployment of Amhwa Biology, in the future, we will actively seek cooperation between terminal preparation manufacturers or international agents and intermediaries to quickly open the international market. At the same time, we will also pay great attention to the cooperation needs of other API products and intermediates, and strive to bring more and better products in production and research to the international market.